

(19)



JAPANESE PATENT OFFICE

**PATENT ABSTRACTS OF JAPAN**

(11) Publication number: **09030979 A**  
(43) Date of publication of application: **04.02.1997**

(51) Int. Cl	<b>A61K 31/725</b>	
	A61K 31/725, A61K 31/725, A61K 31/73, A61K 31/73, C08B 37/08	
(21) Application number:	<b>07207404</b>	(71) Applicant: <b>SEIKAGAKU KOGYO CO LTD</b>
(22) Date of filing:	<b>24.07.1995</b>	(72) Inventor: <b>SUGIURA NOBUO KUSHIMA YOICHI OHIRA ATSUSHI KIMATA HIROHARU GOTO SACHIKO</b>

**(54) THERAPEUTIC AGENT FOR NEUROPATHY**

**(57) Abstract:**

**PROBLEM TO BE SOLVED:** To obtain the subject therapeutic agent comprising a lipid-bonded glycosaminoglycan (lipid bonded GAG) or its salt as an active ingredient, having stretching promoting effect on neurite and recovery promoting action on neurological function, being expected to have reproducing effect on nerve fiber, etc., having extremely low toxicity.

**SOLUTION:** This therapeutic agent for neuropathy comprises a lipid-bonded glycosaminoglycan (lipid bonded GAG) or its salt as an active ingredient, The

lipid bonded GAG, for example, is obtained by specifically cleaving a pyranose ring at the reduced end of GAG by oxidizing the saccharide reside at the reduced end of GAG to form carboxyl at the reduced end, subjecting the resultant substance to a lactone formation reaction, then reacting the lactone with a primary amine of a lipid to bond GAG to the lipid by covalent bond. Chondroitin sulfate, hyaluronic acid, and their salts are preferable as GAG of raw material. A primary amino-containing phospholipid is preferable as the lipid. Dipalmitoyl- L-( $\alpha$ -phosphatidyl)ethanolamine-bonded hyaluronic acid, etc., are preferable as the lipid-bonded GAG. palmitoyl. phosphatidyl.

**COPYRIGHT:** (C)1997,JPO